AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 141 min read$CYTK

Blum Robert I sold $615K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $82.02 ($0.62M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Jul 14, 2026, 7:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 14, 2026, 7:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CYTK
Neutral
high confidence
Mentioned
$CYTK
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The CEO’s open-market sale is disclosed with execution price, share count, and confirmation of a pre-arranged 10b5-1 plan, but no new business developments are provided.

02

Market read

Primarily a sentiment/positioning datapoint; not a fundamental catalyst.

03

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, contracts, or trial updates, the signal is typically weak.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-14 after-hours; reflects 2026-07-13 sale execution.

Background

The article is an SEC Form 4 insider transaction disclosure for Cytokinetics, Inc. (CYTK).

Company-level read

Ticker impact

$CYTKNeutralHigh confidence
Context

CYTOK insider Form 4 shows CEO Robert I. Blum sold 7,500 shares on 2026-07-13 at $82.02 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged Rule 10b5-1 plan, and provides no new company-specific news beyond the sale details.

Market effects

Sector

No sector read-through; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    CYTOKINETICS INC

    Company whose CEO insider sale is disclosed via SEC Form 4.

  • insider
    Blum Robert I

    President and CEO who sold 7,500 shares on 2026-07-13 under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 6
$CYTKMedAI 8/10

CYTOKINETICS INC (CYTK): Results of Operations and Financial Condition

CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Sup

SEC EDGAR 8-K6 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics Secures MHRA Marketing Authorization For MYQORZO In OHCM

Cytokinetics (CYTK) said the UK MHRA granted marketing authorization for MYQORZO (aficamten) to treat adults with obstructive hypertrophic cardiomyopathy, NYHA class II-III. NICE issued positive guidance for eligible patients in England and Wales. Approval cited SEQUOIA-HCM Phase 3 results, with peak oxygen uptake improving vs placebo (1.8 vs 0.0 mL/kg/min, p<0.001).

rttnews.com4 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics' cardiomyopathy drug cleared for NHS use

Cytokinetics said the UK MHRA and NICE cleared its cardiomyopathy drug Myqorzo (aficamten) for NHS use as an add-on to standard therapy in adults with NYHA class II-III obstructive hypertrophic cardiomyopathy. NICE required cost parity with Bristol Myers Squibb’s Camzyos. Myqorzo made about $5m in Q1 sales; Camzyos $314m.

pharmaphorum.com4 min
JUL 24
$CYTKMed

What Makes Cytokinetics' MYQORZO Launch a Game Changer

Cytokinetics (CYTK) is commercializing MYQORZO (aficamten), approved for symptomatic obstructive hypertrophic cardiomyopathy in the U.S., Europe, and China. The U.S. launch began in January 2026 and Europe is planned for Germany in Q2 2026. In 2025, revenue rose to $88.0M and net loss widened to $784.9M, while cash was about $1.22B.

kavout.com6 min
JUN 1
$CYTKMedAI 8/10

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics (Nasdaq: CYTK) said MYQORZO® (aficamten) has launched commercially in Germany, the first European availability, for adults with symptomatic obstructive hypertrophic cardiomyopathy (NYHA II–III). The company cited EU approval in February 2026 based on SEQUOIA-HCM Phase 3 results, including a 1.76 mL/kg/min pVO2 improvement vs 0.0 with placebo over 24 weeks.

manilatimes.net4 min